ERBB2 and metastatic colorectal cancer: The activation of RAS/RAF signaling may be contributing to the low efficacy of T-DXd in HER2-low metastatic colorectal cancers [27] because HER2-low metastatic colorectal cancers are reported with more RAS relative pathway enrichment [23].